Defendant Name:
FibroGen, Inc.
Defendant Type:
Public Company
SIC Code:
9999
CUSIP:
31572Q80
Document Reference:
33-11387
Document Details
Legal Case Name
In the Matter of FibroGen, Inc.
Document Name
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
Document Date
05-Sep-2025
Document Format
Administrative Proceeding
Allegation Type
Issuer Reporting and Disclosure
Document Summary
On September 5, 2025, the SEC instituted settled cease-and-desist proceedings against FibroGen, Inc., stating: "This matter involves false and/or materially misleading statements about the results of
certain cardiovascular safety analyses of FibroGen’s then-primary drug candidate Roxadustat, a
potential therapy for the treatment of anemia in patients with chronic kidney disease."
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Undertaking to Cooperate in Related Action
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:
Civil Penalty
Individual:
$1,250,000.00
Shared:
